SAN FRANCISCO, CA AND NEW YORK, NY / ACCESS Newswire / February 24, 2026 / Unlearn, a leading artificial intelligence company in the clinical development space, today announced its use of data from ...
Patient-level digital twins expected to strengthen evidence generation in Phase1/2 clinical study evaluating VTx-002, a first ...
Unlearn and Merck KGaA have announced a partnership to accelerate drug trials using medical digital twins of patients. Unlearn uses recent developments from deep learning to create digital twins of ...
Throughout the history of medicine, drug developers have tried to make clinical trials faster and more efficient. Artificial intelligence and machine-learning methods are some of the newer approaches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results